Indaptus Therapeutics (NASDAQ:INDP) Posts Earnings Results, Beats Expectations By $0.03 EPS

Indaptus Therapeutics (NASDAQ:INDP) announced its earnings results on Thursday. The company reported ($0.38) earnings per share for the quarter, topping the consensus estimate of ($0.41) by $0.03, Zacks reports.

Indaptus Therapeutics Price Performance

Shares of INDP stock opened at $0.84 on Thursday. The business has a fifty day moving average of $0.86 and a 200 day moving average of $1.09. Indaptus Therapeutics has a 1 year low of $0.70 and a 1 year high of $3.10. The firm has a market capitalization of $11.86 million, a price-to-earnings ratio of -0.49 and a beta of 1.60.

Wall Street Analyst Weigh In

Separately, Maxim Group cut their price objective on shares of Indaptus Therapeutics from $8.00 to $5.00 and set a “buy” rating on the stock in a report on Wednesday, November 13th.

Indaptus Therapeutics Company Profile

Indaptus Therapeutics, Inc, a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, which is in Phase 2 clinical trial.